Familial gene mutation immortalizes deadly skin cancer

Washington, Jan ary 27: An Indian origin scientist and his team analyzed the genomes of 14 family members who were affected by malignant melanoma and found an identical mutation in the gene for telomerase, an enzyme often called ‘immortality enzyme’, in all persons studied.

Telomerase protects the ends of chromosomes from being lost in the process of cell division and, thus, prevents that the cell ages and dies. The inherited gene mutation leads to the formation of a binding site for protein factors in the controlling region of the telomerase gene, causing it to become overactive. As a result, mutated cells overproduce telomerase and hence become virtually immortal.

This spectacular finding of the family analysis prompted the scientists to also look for mutated telomerase genes in non-inherited (sporadic) melanoma, which is much more common than the familial variant.

In most of the tissue samples of melanomas of all stages they found alterations in the telomerase gene switch, which the researchers clearly identified as typical consequences of sun exposure. Even though these mutations were not identical to those found in the melanoma family, they had the same effect: overactive telomerase.

“We don’t believe that the telomerase gene in melanoma is mutated by pure chance, but that it is a so-called driver mutation that drives carcinogenesis,” said Prof. Dr. Rajiv Kumar of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) who conducted the study together with Prof. Dr. Dirk Schadendorf from Essen University Hospital.

This is also confirmed by the surprising incidence of this alteration: The telomerase gene is the most frequently mutated gene in melanoma.

“This is something we hadn’t expected, because malignant melanoma has been genetically analyzed thoroughly. But this mutation always seems to have been overlooked,” said Kumar.

Kumar, Dirk Schadendorf and their teams are hoping that the alterations in the telomerase gene may be a starting point for developing novel treatment methods for malignant melanoma. (ANI)